Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price reached a new 52-week low on Thursday . The company traded as low as GBX 5 and last traded at GBX 5.90, with a volume of 143181 shares. The stock had previously closed at GBX 5.50.
Allergy Therapeutics Stock Up 1.4%
The company has a market capitalization of £378.69 million, a P/E ratio of -6.16, a PEG ratio of -30.70 and a beta of 0.87. The firm’s 50 day moving average price is GBX 7.66 and its two-hundred day moving average price is GBX 9.76. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
